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Background: Both taxanes, docetaxel and cabazitaxel, are effective treatments for metastatic castration-resistant prostate cancer
(mCRPC). However, resistance to taxanes is common. Our objective was to investigate mechanisms of taxane resistance in
prostate cancer.
Methods: Two docetaxel-resistant patient-derived xenografts (PDXs) of CRPC were established (PC339-DOC and PC346C-DOC)
in male athymic nude mice by frequent intraperitoneal administrations of docetaxel. Next-generation sequencing was performed
on PDX tissue pre- and post-docetaxel resistance and gene expression profiles were compared. [14C]-docetaxel and [14C]-
cabazitaxel uptake assays in vitro and cytotoxicity assays were performed to validate direct involvement of transporter genes in
taxane sensitivity.
Results:Organic anion-transporting polypeptide (SLCO1B3), an influx transporter of docetaxel, was significantly downregulated in
PC346C-DOC tumours. In accordance with this finding, intratumoural concentrations of docetaxel and cabazitaxel were
significantly decreased in PC346C-DOC as compared with levels in chemotherapy-naive PC346C tumours. In addition, silencing of
SLCO1B3 in chemo-naive PC346C resulted in a two-fold decrease in intracellular concentrations of both taxanes. Overexpression
of SLCO1B3 showed higher sensitivity to docetaxel and cabazitaxel.
Conclusions: The SLCO1B3 determines intracellular concentrations of docetaxel and cabazitaxel and consequently influences
taxane efficacy. Loss of the drug transporter SLCO1B3 may drive taxane resistance in prostate cancer.
To date, B25% of patients diagnosed with prostate cancer will
eventually progress to metastatic castration-resistant prostate
cancer (mCRPC) (Rane et al, 2012). The mCRPC patients
are generally treated with docetaxel as standard first-line
chemotherapy. Unfortunately, there is a large variability in
response to docetaxel treatment among patients (Petrylak et al,
2004; Tannock et al, 2004; de Bono et al, 2010). Whereas some
patients show prolonged responses, others respond poorly and
progress rapidly. Among new options for docetaxel-resistant
patients, cabazitaxel is a strong alternative taxane with proven
efficacy in docetaxel-resistant patients (de Bono et al, 2010).
We previously showed that higher intratumoural concentrations
of cabazitaxel in docetaxel-resistant tumours might lead to
stronger antitumour activity (De Morree et al, 2016). Hence, it is
highly relevant to determine tumour factors that may be linked
to docetaxel resistance and cabazitaxel sensitivity. Such
predictive biomarkers of taxane resistance will allow to
define patients who are less likely to benefit from continued
treatment with docetaxel, and thus might be candidates for
treatment with cabazitaxel.
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In order to mimic the development of docetaxel resistance in
patients, we set out to develop docetaxel resistance in a selection
of patient-derived xenografts (PDXs) of prostate cancer. The PDX
model has been demonstrated to largely resemble the complexity
of prostate cancer including molecular diversity, cellular hetero-
geneity and histology (Kopetz et al, 2012). To investigate
mechanisms of docetaxel resistance, we performed next-genera-
tion sequencing (NGS) and compared gene expression profiles of
the created docetaxel-resistant tumours vs their parental tumours.
We identified downregulation of SLCO1B3 as a potential
mechanism of taxane resistance in CRPC. We show that silencing
of SLCO1B3 resulted in decreased uptake of both docetaxel and
cabazitaxel, whereas SLCO1B3 overexpression enhanced taxane
sensitivity.
MATERIALS AND METHODS
Drugs. Docetaxel and cabazitaxel (Sanofi, Vitry-sur-Seine, France)
formulations were prepared in polysorbate-80-ethanol (1 : 1, v/v)
and further diluted in 5% (w/v) glucose solution to a final
concentration of 2.5mgml 1 for in vivo experiments. In uptake
assays, [14C]-docetaxel and [14C]-cabazitaxel (specific activity: 83–
86mCi  1mmol l 1; Sanofi-Aventis Deutschland GmbH, Frank-
furt, Germany) were used.
Development of docetaxel-resistant PDXs. The PC339, PC346C
and PC374 xenografts with respectively low, moderate and high
sensitivity to docetaxel were selected from the Erasmus MC
prostate cancer PDX panel (van Weerden et al, 2009). The three
selected PDXs were derived from patients progressive under
standard androgen depletion therapy (ADT). Some molecular
characteristics of the PDX models are listed in Supplementary
Table 1. Docetaxel resistance was developed as described
previously (De Morree et al, 2016). In short, tumour fragments
of PDXs were subcutaneously transplanted on 8-week-old nonca-
strated male NMRI nude mice (NMRI-Foxn1nu; Taconic, Hudson,
NY, USA) and when tumours were established, mice received one
bolus injection of docetaxel (33mg kg 1) intraperitoneally (i.p.)
every 14 days until tumours progressed. Mice were not castrated, as
it was previously shown that androgen levels in male mice
resemble the androgen levels of chemically castrated men,
originating from adrenal androgens (Sedelaar et al, 2013). Tumour
fragments were consecutively passaged until growth rates of
docetaxel-treated tumours were similar to those of the chemo-
naive original tumour. All experiments were approved by the
Animal Experiments Committee under the Dutch Experiments on
Animals Act in adherence of the European Convention for
Protection of Vertebrate Animals used for Experimental Purposes
(Directive 2010/63/EU).
Assessment of antitumour activity. Antitumour activity of
taxanes in chemo-naive and docetaxel-resistant PDXs was
determined after a single i.p. injection of docetaxel 33mg kg 1
or cabazitaxel 33mg kg 1, or 0.9% (w/v) NaCl at a tumour volume
of 300mm3 as described previously (De Morree et al, 2016). In
short, tumour volumes were measured twice a week by caliper.
Antitumour activity of taxanes was monitored using the log cell kill
formula (formula 1). This formula theoretically models the
working mechanism of taxanes, assuming that a proportion of
cells are killed after a single treatment while taking into account
tumour doubling time.
Log cell kill ¼ TC daysð Þ= 3:32  Tdð Þ
Formula 1: Log cell kill closely mimics clinical end points such as
disease progression and takes into account how fast the tumour
grows (tumour doubling time) in relation with the tumour growth
delay induced by treatment according to the formula. T is the
median time in days to reach a tumour volume of 1000mm3 in the
treated mice. C is the median time in days to reach the same
tumour volume in the control mice. Td is the tumour doubling
time, derived from a log-linear growth plot of the control tumours
in exponential growth phase. Log cell kill values are translated to
antitumour activity as follows (Lloyd, 1975; Schabel et al, 1977;
Corbett et al, 2003): 0.7–1.2¼ þ ; 1.3–1.9¼ þ þ ; 2.0–2.8¼ þ
þ þ ; and 42.8¼ þ þ þ þ . Resistance to taxanes was defined
as log cell kill o0.7.
NGS of PDXs. Three independent tumours of each PDX, docetaxel-
naive PC339, PC346C and PC374, and of docetaxel-resistant PC339-
DOC and PC346C-DOC, were analysed by NGS/RNA seq. In brief,
total RNA was extracted using RNA-Bee reagent (Tel-Test, Inc.
Friendswood, TX, USA) according to the manufacturer’s instruc-
tions. The RNA quantity and quality were analysed using Agilent
Laboratory-on-Chip analysis (Agilent Bioanalyzer 2100, Agilent
Technologies, Santa Clara, CA, USA). RNA samples with RNA
Integrity Number (RIN) X7 were included. Library and paired-end
RNA sequencing were executed by AROS (Applied Biotechnologies,
Aarhus, Denmark) on a Illumina HiSeq 2000 with a sequencing
depth of minimum 35 Mio reads.
mRNA expression validation using real-time PCR. Total RNA
was isolated from PC346C and PC346C-DOC tumours to validate the
expression levels of SLCO1B3. In addition, RNA from abiraterone-
and enzalutamide-resistant tumours PC346Enza and PC346Abi101
that were previously developed (van Soest et al, 2013; Van Soest et al,
2015) was isolated. The SLCO1B3 mRNA (Taqman Assay On
Demand, Hs00251986_m1, Applied Biosystems, Thermo Fisher
Scientific, Waltham, MA, USA) was measured using a 7500 Fast
Real-Time PCR System (Applied Biosystems). Gene expression was
normalised using the DCt method against housekeeping genes
hypoxanthineguanine phosphoribosyltransferase (HPRT, Taqman
assay 4310890E) and Porphobilinogen Deaminase (PBGD, Taqman
assay Hs00609297_m1).
Bioinformatics analysis. A detailed description of the bioinfor-
matics approach and analysis is provided in the Supplementary
Methods. Gene expression profiles of chemotherapy-naive and
docetaxel-resistant tumours were compared. The mRNA gene
expression profiles were generated of which the expression was
significantly altered in the docetaxel-resistant tumours. A false
discovery rate (FDR) of o0.05 was used.
Gene silencing of taxane-related drug transporters. To evaluate
the involvement of drug transporters in taxane efficacy, the top 10
of transporters that correlated with docetaxel and the top 10
transporters that correlated with cabazitaxel sensitivity were
selected (see Supplementary Methods for details on the selection
process). Genes were silenced in parental PC346C cells using the
Sigma Transporter Silencing Bank (Sigma Mission siRNA of Ion
Channel and Transporter Panel S106100, Sigma-Aldrich, St Louis,
MO, USA) focussing on adenosine triphosphate-binding cassette
(ABC) transporters and solute carrier (SLCs) families that were
correlated with taxane sensitivity (for further details see
Supplementary Methods). In short, PC346C cells were transfected
with siRNA pools targeting various transporters. After 48 h, a
[14C]-docetaxel and [14C]-cabazitaxel uptake assay was performed.
Retained [14C]-cabazitaxel and [14C]-docetaxel levels were counted
with a scintillation counter and normalised to levels observed in
control cells transfected with a nontargeting siRNA pool
(Zimmerman et al, 2016).
Intratumoural taxane concentration. Mice bearing docetaxel-
naive or docetaxel-resistant PDXs received a single intraperitoneal
injection of docetaxel 33mg kg 1 or cabazitaxel 33mg kg 1 at a
tumour volume of 300mm3 and were killed after 7 days. Tumour
tissue was homogenised in lithium-heparinised human plasma
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(1 : 5 w/v) and processed for further analysis by a validated liquid
chromatography/tandem mass spectrometry (LC/MS-MS) assay to
determine intratumoural docetaxel and cabazitaxel concentrations
as previously described (Engels et al, 2006; de Bruijn et al, 2012; de
Morree et al, 2016).
Cell proliferation assays. To substantiate the role of SLCO1B3 in
taxane sensitivity, SLCO1B3-negative PC339C and PC346C-DCC-
G cells were stably transfected with a SLCO1B3 or GFP (control)
expression construct (see Supplementary Methods). The
SLCO1B3-overexpressing cells and GFP-control cells were seeded
in a 96-well plate at a concentration of 2500 cells per well and
incubated for 10 days with docetaxel or cabazitaxel (serial
concentration range 0–10 nM). Proliferation was assessed using
PrestoBlue Cell Viability reagent (Thermo Fisher Scientific,
Waltham, MA, USA). Data are expressed as mean±s.e.m. of
three independent experiments with at least six replicates per
condition. The IC50 values were determined using GraphPad Prism
5.0 (GraphPad Software, San Diego, CA, USA). The IC50 values
were compared using the extra sum-of-squares F-test with a
boundary for significance of Pp0.05.
RESULTS
Generation of docetaxel-resistant PDXs of prostate cancer. In
order to develop docetaxel resistance in vivo, PC339, PC346C and
PC374 tumours were serially passaged under docetaxel pressure.
The chemotherapy-naive PC339 PDX was characterised by a poor
response to docetaxel with log cell kill values of 0.42 (log cell kill
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Figure 1. Taxane response in docetaxel-naive and docetaxel-resistant PDXs. Tumour-bearing mice were treated with a single injection of either
placebo (green), docetaxel 33mgkg1 (black) or cabazitaxel 33mgkg 1 (red). Tumour volume was measured twice a week. Each line represents a
single mouse. Log cell kill o0.7 was considered as resistant. Table insert summarises log cell kill values and antitumour activity of docetaxel and
cabazitaxel in the various PDX models. A full colour version of this figure is available at the British Journal of Cancer journal online.
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40.7 is considered therapy responsive) (Figure 1). Within 4
mouse passages, a docetaxel-resistant variant, PC339-DOC, was
established translating in a log cell kill value of 0.18. In contrast,
the chemotherapy-naive PC346C was relatively sensitive to
docetaxel treatment (log cell kill value of 1.0) and remained
responsive for almost 1 year after the first docetaxel treatment
before acquiring resistance (log cell kill 0.20). Finally, the
chemotherapy-naive PC374 was extremely sensitive to docetaxel
treatment (log cell kill 1.6) and we were unable to create a
resistant counterpart of this PDX. Cabazitaxel was at least as
potent as docetaxel with corresponding log cell kill values of
42.8, 1.2 and 1.8 for the docetaxel-naive PC339, PC346C and
PC374, respectively. Interestingly, cabazitaxel exhibited high
sensitivity in PC339-DOC (log cell kill42.8), whereas it showed
cross-resistance with docetaxel in PC346C-DOC (log cell kill
0.23) (Figure 1).
Significant downregulation of SLCO1B3 expression in doce-
taxel-resistant PDX. To unravel potential mechanisms of
resistance, we performed NGS/RNA seq between parental
chemo-naive and docetaxel-resistant PDX tumours and identified
differentially expressed genes based on a FDR of 0.05
(see Table 1 for the top 15 gene list). The docetaxel uptake
transporter SLCO1B3 was the most significantly downregulated
gene in PC346C-DOC. The SLCO1B3 was neither expressed in the
docetaxel-naive PC339 nor in the docetaxel-resistant PC339-DOC.
Validation with qPCR confirmed the substantial downregulation of
SLCO1B in PC346C-DOC (Figure 2). To rule out that SLCO1B3
downregulation was caused by serial passaging of PC346C rather
than by docetaxel treatment, we showed that SLCO1B3 expression
was retained in parental PC346C tumours during propagation
(Supplementary Figure 1).
Downregulation of SLCO1B3 in abiraterone- and enzalutamide-
resistant cells. We have previously shown cross-resistance
between AR-targeted therapies, such as abiraterone and enzaluta-
mide, and docetaxel in vitro and in vivo (van Soest et al, 2013;
van Soest et al, 2015). Therefore, SLCO1B3 expression was also
evaluated in PC346C cell lines with acquired resistance to
abiraterone (PC346abi101) and enzalutamide (PC346enza). Similar
to PC346C-DOC, SLCO1B3 expression was low in both
PC346abi101 and PC346enza cells (Figure 2).
Decreased intratumoural taxane concentrations in docetaxel-
resistant PDXs. As SLCO1B3 is a known transporter of docetaxel,
downregulation of SLCO1B3 most likely result in reduced
intratumoural taxane concentrations, inferring the observed
resistant phenotype of PC346C-DOC. Indeed, intratumoural
concentrations of docetaxel were significantly lower in PC346C-
DOC as compared with chemo-naive PC346C tumours (respec-
tively P¼ 0.003 and P¼ 0.0006; Figure 3). As expected from the
observed cross-resistance between docetaxel and cabazitaxel,
intratumoural cabazitaxel levels were also reduced and not
different from docetaxel in PC346C-DOC. In contrast, and in line
with the efficacy of cabazitaxel in PC339 and PC339-DOC
tumours, cabazitaxel levels were significantly higher than docetaxel
levels in both PC339 (P¼ 0.005) and PC339-DOC tumours
(P¼ 0.01; Figure 3). The significance of SLCO1B3 in the regulation
of effective intratumoural levels of taxanes is provided in Figure 4.
Table 1. Top 15 genes significantlya up- or down-regulated in the parental vs the docetaxel-resistant PDX
PC346C vs
PC346C-DOC
Functionb
Log fold
change
PC339 vs
PC339-DOC
Functionb
Log fold
change
SLCO1B3 Organic anion transmembrane transporter
activity
6.03 SPATA21 Calcium ion binding  2.90
RBM24 30-UTR binding and nucleotide binding 5.07 MSMB Member of the immunoglobulin binding
factor family
2.69
HES7 Protein dimerisation activity and
transcription factor binding
4.02 GRIP2 Undefined  2.46
TNFRSF18 tumour necrosis factor-activated receptor
activity
3.71 EGFLAM Glycosaminoglycan binding 2.38
VANGL2 Regulation of planar cell polarity 3.70 POTEM Undefined 2.29
SLC30A4 Zinc ion transmembrane transporter
activity
3.06 AFAP1 Actin binding and phospholipid binding  2.20
ATP2B4 Calmodulin binding and sodium channel
regulator activity
2.61 USH2A Collagen binding and myosin binding 2.08
FADS2 Stearoyl-CoA 9-desaturase activity and
iron ion binding
2.44 TSHR Thyroid-stimulating hormone receptor
activity
1.93
MTRNR2L10 Neuroprotective and antiapoptotic factor 2.36 KRT6A Structural constituent of cytoskeleton 1.83
GPR88 G protein-coupled receptor activity 2.26 ZNF407 May be involved in transcriptional regulation  1.82
MARCKS Cell motility, phagocytosis, membrane
trafficking and mitogenesis
1.97 NEB Structural constituent of muscle and actin
binding
1.80
UTRN Protein kinase binding, calcium ion
binding
1.78 HLA-A Peptide antigen binding and receptor
binding
1.72
COL7A1 Serine-type endopeptidase inhibitor
activity
1.75 CTAG2 Undefined  1.66
MT2A Binding of heavy metals 1.61 TMEM176B Undefined 1.59
IQGAP2 Regulate cell morphology and motility 1.59 KRT17 MHC class II protein binding and structural
constituent of cytoskeleton
1.49
Abbreviations: MHC¼major histocompatibility complex; PDX¼patient-derived xenograft; UTR¼untranslated region.
aFalse discovery rate was o0.05 for all genes.
bGene function was derived from www.genecards.org.
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Knockdown of SLCO1B3 significantly decreased cellular uptake
of taxanes. To determine whether other drug transporters could
have contributed to the decreased concentrations of docetaxel and
cabazitaxel observed in PC346C-DOC tumours, an siRNA screen
of putative taxane drug transporters was performed. The only
significant (50%) reduction in uptake of docetaxel (P¼ 0.01) and
cabazitaxel (P¼ 0.0003) was observed when PC346C cells were
transfected with the SLCO1B3 siRNA pool (Figure 5 and
Supplementary Figure 2).
Higher sensitivity to taxanes in SLCO1B3-overexpressing cells.
To further substantiate the role of SLCO1B3 in taxane sensitivity,
cell viability was measured after docetaxel and cabazitaxel
exposure in SLCO1B3-negative PC339C-GFP and SLCO1B3-
overexpressing PC339C cells (see Supplementary Figure 3 for
SLCO1B3 expression levels). The SLCO1B3-overexpressing
PC339 cells were more sensitive to taxane treatment than the
control-transfected PC339C-GFP cells. A similar correlation
between SLCO1B3 and taxane sensitivity was seen in
SLCO1B3-transfected, originally SLCO1B3-negative, castration-
resistant PC346C-DCC-G subline (Figure 6).
DISCUSSION
Predictive biomarkers for resistance to taxane chemotherapy are
an unmet medical need in the management of mCRPC. Insights
into the mechanisms of taxane resistance are crucial to identify
and develop reliable predictive biomarkers and potential
therapeutic targets. Here we show that downregulation of the
influx transporter SLCO1B3 is associated with taxane resistance
in a PDX model of prostate cancer, pointing towards a role for
SLCO1B3 in taxane sensitivity through regulation of drug
uptake, determining intratumoural concentrations and conse-
quently efficacy. As such, SLCO1B3 may be a potential
biomarker of docetaxel resistance that warrants further clinical
validation.
The generation of two unique docetaxel-resistant PDX models,
PC346C-DOC and PC339-DOC, allowed to screen for somatic
mutations underlying the resistant phenotype that could have
been acquired during the development of docetaxel resistance.
Interestingly, we did not find any treatment-induced somatic
variants in the transcriptome of either PDX. This finding and the
difference in time to development of docetaxel resistance of these
models, as well as their contrasting response to cabazitaxel,
suggest that PC339-DOC and PC346C-DOC express different
resistance mechanisms that are likely to be involved in
chemoresistance.
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Figure 3. Intratumoural concentrations of docetaxel and cabazitaxel in parental vs docetaxel-resistant PDXs. Intratumoural concentrations were
measured in docetaxel-naive and docetaxel-resistant PDXs at 7 days after a single dose with either docetaxel or cabazitaxel. Intratumoural
concentrations of both docetaxel and cabazitaxel were significantly reduced in PC346C-DOC compared with PC346C. *Po0.05,
NS¼nonsignificant.
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Differentially expressed genes that correlated to docetaxel
resistance identified SLCO1B3 as an important gene associated
with docetaxel resistance in PC346C-DOC. An extensive siRNA
screen further revealed that the role of other ABC transporters and
transporters from the SLC families, which were previously linked
to taxane sensitivity, was less pronounced compared with
SLCO1B3 in this model. The lack of SLCO1B3 expression in
naive PC339 and resistant PC339-DOC may explain the relative
low sensitivity to docetaxel in this intrinsically resistant PDX,
underscoring the relevance of SLCO1B3 in docetaxel sensitivity.
This is further substantiated by the observation that overexpressing
SLCO1B3 in PC339C cells indeed resulted in increased sensitivity
to docetaxel. Interestingly, and in contrast to PC346C and
PC346C-DOC, PC339 and PC339-DOC were highly sensitive for
cabazitaxel that was further augmented when overexpressing
SLCO1B3. These data suggest that cabazitaxel influx and
intratumoural levels also benefit from SLCO1B3 expression. This
observation contrasts with previous reports indicating that
cabazitaxel uptake may rely more on transmembrane diffusion
than carrier-mediated translocation across the plasma membrane
because of its higher lipophilicity as compared with docetaxel
(Azarenko et al, 2014; Vrignaud et al, 2014). Clearly, further
experiments are required to define whether cabazitaxel is a
substrate of SLCO1B3 and its importance for intracellular
cabazitaxel levels.
The SLCO1B3 has previously been shown to be expressed in at
least 50% of prostate cancer specimens with increased expression
in mCRPC compared with primary prostate cancer (Pressler et al,
2011; Wright et al, 2011). Furthermore, SLCO1B3 expression has
been linked to the hormonal status of prostate cancer and to the
response to androgen deprivation therapies, as it is also an influx
transporter of testosterone (Hamada et al, 2008). Of note, in our
enzalutamide- and abiraterone-resistant cell lines (van Soest et al,
2013, 2015) that represent cross-resistance with docetaxel,
SLCO1B3 expression was lost, suggesting that pretreatment with
hormonal agents, like enzalutamide and abiraterone, may affect
taxane sensitivity via reduction of SLCO1B3 expression. Therefore,
SLCO1B3 may not only mediate the cellular uptake of docetaxel,
but may also alter the androgen responsiveness of the cell. This
potential mechanism of cross-resistance may have implications for
potential treatment sequences in the management of prostate
cancer. Such possible relationship between SLCO1B3 and andro-
gen status of the patient, inflicted either by conventional ADT or
by the use of novel AR-targeted agents, may be particularly
relevant in light of recent data, showing a robustly greater survival
benefit by docetaxel when given in addition to ADT in patients
with metastatic hormone-sensitive prostate cancer (mHSPC) as
compared when given at the time of castration resistance (James
et al, 2015; Sweeney et al, 2015). The value of SLCO1B3 expression
as a potential candidate biomarker for taxane response in mCRPC
and mHSPC patients requires a prospective clinical study in which
tumour lesions are biopsied pre and post taxane treatment. As an
alternative, circulating tumour cells may be considered as a liquid
biopsy to evaluate SLCO1B3 expression over time and determine
its predictive value.
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Cell
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Figure 4. Mechanism of SLCO1B3-mediated resistance to docetaxel. Docetaxel-responsive cells express SLCO1B3. The SLCO1B3 is a known
influx transporter of docetaxel, and transports docetaxel into the cell. Cabazitaxel may also be a potential substrate of SLCO1B3, but this
hypothesis needs further experimental validation. We previously showed that intratumoural concentrations of cabazitaxel were generally higher in
docetaxel-naive tumours compared with docetaxel. As docetaxel or cabazitaxel enter the cell, they inhibit microtubule dynamics, leading to a cell
cycle arrest in th G2/M phase and eventually to apoptosis. In docetaxel-resistant cells, SLCO1B3 expression is downregulated. We found that
intratumoural concentrations of both docetaxel and cabazitaxel were decreased in docetaxel-resistant PC346C-DOC xenograft tumours,
compared with the parental PC346C xenograft tumours. Experiments in which SLCO1B3 was silenced in PC346C cells showed decreased uptake
of docetaxel and cabazitaxel, confirming that SLCO1B3 is at least partly involved in modulating intracellular concentrations of docetaxel and
cabazitaxel. Decreased intratumoural concentrations leads to decreased response to therapy as was previously shown (De Morree et al, 2016).
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Figure 5. Silencing of SLCO1B3 leads to decreased uptake of
docetaxel and cabazitaxel. Uptake and retention of [14C]-docetaxel
and [14C]-cabazitaxel was measured in PC346C cells after silencing
SLCO1B3. The levels of cabazitaxel and docetaxel taken up and
retained in the cells were compared with the uptake of taxanes in cells
transfected with CTRL siRNA. An average±s.d. is shown of n¼3
measurements. *Po0.05 compared with the uptake in the control.
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CONCLUSIONS
We have shown that SLCO1B3 expression is associated with taxane
resistance. In addition, SLCO1B3 may also have a role in cross-
resistance with hormonal agents like enzalutamide and abiraterone.
Clinical studies are needed to further investigate the potential role
of SLCO1B3 as biomarker in patients with mCRPC treated with
taxane chemotherapy.
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